1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Three	_	_	CD	_	_	_	_	_
2	key	_	_	JJ	_	_	_	_	_
3	immunological	_	_	JJ	_	_	_	_	_
4	features	_	_	NNS	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	lentiviral	_	_	JJ	_	_	_	_	_
7	infection	_	_	NN	_	_	_	_	_
8	are	_	_	VBP	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	lack	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	an	_	_	DT	_	_	_	_	_
13	effective	_	_	JJ	_	_	_	_	_
14	immune	_	_	JJ	_	_	_	_	_
15	response	_	_	NN	_	_	_	_	_
16	against	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	virus	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	susceptibility	_	_	NN	_	_	_	_	_
21	to	_	_	TO	_	_	_	_	_
22	opportunistic	_	_	JJ	_	_	_	_	_
23	pathogens	_	_	NNS	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	generalized	_	_	VBN	_	_	_	_	_
27	immune	_	_	JJ	_	_	_	_	_
28	activation	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	underlying	_	_	JJ	_	_	_	_	_
3	mechanisms	_	_	NNS	_	_	_	_	_
4	that	_	_	WDT	_	_	_	_	_
5	lead	_	_	VBP	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	these	_	_	DT	_	_	_	_	_
8	immunologic	_	_	JJ	_	_	_	_	_
9	alterations	_	_	NNS	_	_	_	_	_
10	are	_	_	VBP	_	_	_	_	_
11	complex	_	_	JJ	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	interrelated	_	_	VBN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Regulatory	_	_	JJ	_	_	_	_	_
2	T	_	_	NN	_	_	_	_	_
3	cells	_	_	NNS	_	_	_	_	_
4	(	_	_	-LRB-	_	_	_	_	_
5	Treg	_	_	NNP	_	_	_	_	_
6	)	_	_	-RRB-	_	_	_	_	_
7	are	_	_	VBP	_	_	_	_	_
8	thought	_	_	VBN	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	contribute	_	_	VB	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	control	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	excessive	_	_	JJ	_	_	_	_	_
16	immune	_	_	JJ	_	_	_	_	_
17	activation	_	_	NN	_	_	_	_	_
18	on	_	_	IN	_	_	_	_	_
19	one	_	_	CD	_	_	_	_	_
20	hand	_	_	NN	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	suppression	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	anti-viral	_	_	JJ	_	_	_	_	_
26	response	_	_	NN	_	_	_	_	_
27	on	_	_	IN	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	other	_	_	JJ	_	_	_	_	_
30	hand	_	_	NN	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	Such	_	_	JJ	_	_	_	_	_
2	Treg-mediated	_	_	JJ	_	_	_	_	_
3	suppression	_	_	NN	_	_	_	_	_
4	can	_	_	MD	_	_	_	_	_
5	render	_	_	VB	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	host	_	_	NN	_	_	_	_	_
8	immune	_	_	JJ	_	_	_	_	_
9	system	_	_	NN	_	_	_	_	_
10	unable	_	_	JJ	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	clear	_	_	VB	_	_	_	_	_
13	chronic	_	_	JJ	_	_	_	_	_
14	infections	_	_	NNS	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	During	_	_	IN	_	_	_	_	_
2	chronic	_	_	JJ	_	_	_	_	_
3	human	_	_	JJ	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	simian	_	_	JJ	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	or	_	_	CC	_	_	_	_	_
8	feline	_	_	JJ	_	_	_	_	_
9	immunodeficiency	_	_	NN	_	_	_	_	_
10	virus	_	_	NN	_	_	_	_	_
11	infection	_	_	NN	_	_	_	_	_
12	(	_	_	-LRB-	_	_	_	_	_
13	HIV-1	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	SIV	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	FIV	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	respectively	_	_	RB	_	_	_	_	_
21	)	_	_	-RRB-	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	Treg	_	_	NNP	_	_	_	_	_
24	cells	_	_	NNS	_	_	_	_	_
25	are	_	_	VBP	_	_	_	_	_
26	capable	_	_	JJ	_	_	_	_	_
27	of	_	_	IN	_	_	_	_	_
28	suppressing	_	_	VBG	_	_	_	_	_
29	antiviral	_	_	JJ	_	_	_	_	_
30	responses	_	_	NNS	_	_	_	_	_
31	in	_	_	IN	_	_	_	_	_
32	vitro	_	_	NN	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	Our	_	_	PRP$	_	_	_	_	_
2	lab	_	_	NN	_	_	_	_	_
3	has	_	_	VBZ	_	_	_	_	_
4	shown	_	_	VBN	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	Treg	_	_	NNP	_	_	_	_	_
7	suppression	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	antiviral	_	_	JJ	_	_	_	_	_
10	responses	_	_	NNS	_	_	_	_	_
11	is	_	_	VBZ	_	_	_	_	_
12	also	_	_	RB	_	_	_	_	_
13	exerted	_	_	VBN	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	vivo	_	_	NN	_	_	_	_	_
16	during	_	_	IN	_	_	_	_	_
17	chronic	_	_	JJ	_	_	_	_	_
18	FIV	_	_	NN	_	_	_	_	_
19	infection	_	_	NN	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	that	_	_	IN	_	_	_	_	_
22	transient	_	_	JJ	_	_	_	_	_
23	depletion	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	CD25+	_	_	NNP	_	_	_	_	_
26	Treg	_	_	NNP	_	_	_	_	_
27	cells	_	_	NNS	_	_	_	_	_
28	improved	_	_	VBD	_	_	_	_	_
29	the	_	_	DT	_	_	_	_	_
30	antiviral	_	_	JJ	_	_	_	_	_
31	response	_	_	NN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	Treg	_	_	NN	_	_	_	_	_
2	cells	_	_	NNS	_	_	_	_	_
3	thus	_	_	RB	_	_	_	_	_
4	contribute	_	_	VBP	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	viral	_	_	JJ	_	_	_	_	_
7	persistence	_	_	NN	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	lentiviral	_	_	JJ	_	_	_	_	_
10	infection	_	_	NN	_	_	_	_	_
11	by	_	_	IN	_	_	_	_	_
12	suppressing	_	_	VBG	_	_	_	_	_
13	adaptive	_	_	JJ	_	_	_	_	_
14	immune	_	_	JJ	_	_	_	_	_
15	responses	_	_	NNS	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	role	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	Treg	_	_	NNP	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	suppression	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	innate	_	_	JJ	_	_	_	_	_
11	immune	_	_	JJ	_	_	_	_	_
12	system	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	susceptibility	_	_	NN	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	opportunistic	_	_	JJ	_	_	_	_	_
17	infections	_	_	NNS	_	_	_	_	_
18	has	_	_	VBZ	_	_	_	_	_
19	been	_	_	VBN	_	_	_	_	_
20	much	_	_	RB	_	_	_	_	_
21	less	_	_	RBR	_	_	_	_	_
22	studied	_	_	VBN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	have	_	_	VBP	_	_	_	_	_
3	employed	_	_	VBN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	intracellular	_	_	JJ	_	_	_	_	_
6	opportunistic	_	_	JJ	_	_	_	_	_
7	pathogen	_	_	NN	_	_	_	_	_
8	Listeria	_	_	NNP	_	_	_	_	_
9	monocytogenes	_	_	NN	_	_	_	_	_
10	(	_	_	-LRB-	_	_	_	_	_
11	Lm	_	_	NNP	_	_	_	_	_
12	)	_	_	-RRB-	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	probe	_	_	VB	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	immune	_	_	JJ	_	_	_	_	_
17	defects	_	_	NNS	_	_	_	_	_
18	associated	_	_	VBN	_	_	_	_	_
19	with	_	_	IN	_	_	_	_	_
20	FIV	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Using	_	_	VBG	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	immune	_	_	JJ	_	_	_	_	_
4	challenge	_	_	NN	_	_	_	_	_
5	model	_	_	NN	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	we	_	_	PRP	_	_	_	_	_
8	found	_	_	VBD	_	_	_	_	_
9	that	_	_	IN	_	_	_	_	_
10	FIV-infected	_	_	JJ	_	_	_	_	_
11	cats	_	_	NNS	_	_	_	_	_
12	have	_	_	VBP	_	_	_	_	_
13	an	_	_	DT	_	_	_	_	_
14	impaired	_	_	VBN	_	_	_	_	_
15	innate	_	_	JJ	_	_	_	_	_
16	response	_	_	NN	_	_	_	_	_
17	that	_	_	WDT	_	_	_	_	_
18	fails	_	_	VBZ	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	gain	_	_	VB	_	_	_	_	_
21	initial	_	_	JJ	_	_	_	_	_
22	control	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	bacterial	_	_	JJ	_	_	_	_	_
25	replication	_	_	NN	_	_	_	_	_
26	prior	_	_	RB	_	_	_	_	_
27	to	_	_	TO	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	adaptive	_	_	JJ	_	_	_	_	_
30	immune	_	_	JJ	_	_	_	_	_
31	response	_	_	NN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	also	_	_	RB	_	_	_	_	_
3	showed	_	_	VBD	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	locally	_	_	RB	_	_	_	_	_
6	delivered	_	_	VBN	_	_	_	_	_
7	interleukin	_	_	NN	_	_	_	_	_
8	15	_	_	CD	_	_	_	_	_
9	(	_	_	-LRB-	_	_	_	_	_
10	IL-15	_	_	NNP	_	_	_	_	_
11	)	_	_	-RRB-	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	a	_	_	DT	_	_	_	_	_
14	cytokine	_	_	NN	_	_	_	_	_
15	known	_	_	VBN	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	activate	_	_	VB	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	stimulate	_	_	VB	_	_	_	_	_
20	natural	_	_	JJ	_	_	_	_	_
21	killer	_	_	NN	_	_	_	_	_
22	(	_	_	-LRB-	_	_	_	_	_
23	NK	_	_	NNP	_	_	_	_	_
24	)	_	_	-RRB-	_	_	_	_	_
25	cells	_	_	NNS	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	significantly	_	_	RB	_	_	_	_	_
28	restored	_	_	VBN	_	_	_	_	_
29	innate	_	_	JJ	_	_	_	_	_
30	immune	_	_	JJ	_	_	_	_	_
31	function	_	_	NN	_	_	_	_	_
32	as	_	_	IN	_	_	_	_	_
33	measured	_	_	VBN	_	_	_	_	_
34	by	_	_	IN	_	_	_	_	_
35	Lm	_	_	NNP	_	_	_	_	_
36	clearance	_	_	NN	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	Further	_	_	JJR	_	_	_	_	_
2	investigation	_	_	NN	_	_	_	_	_
3	revealed	_	_	VBD	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	NK	_	_	NNP	_	_	_	_	_
6	cells	_	_	NNS	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	NK	_	_	NNP	_	_	_	_	_
9	T	_	_	NNP	_	_	_	_	_
10	cells	_	_	NNS	_	_	_	_	_
11	(	_	_	-LRB-	_	_	_	_	_
12	NKT	_	_	NNP	_	_	_	_	_
13	)	_	_	-RRB-	_	_	_	_	_
14	from	_	_	IN	_	_	_	_	_
15	FIV-infected	_	_	JJ	_	_	_	_	_
16	cats	_	_	NNS	_	_	_	_	_
17	display	_	_	VBP	_	_	_	_	_
18	heightened	_	_	VBN	_	_	_	_	_
19	constitutive	_	_	JJ	_	_	_	_	_
20	levels	_	_	NNS	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	proliferation	_	_	NN	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	apoptosis	_	_	NN	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	a	_	_	DT	_	_	_	_	_
28	defective	_	_	JJ	_	_	_	_	_
29	response	_	_	NN	_	_	_	_	_
30	to	_	_	TO	_	_	_	_	_
31	Lm	_	_	NN	_	_	_	_	_
32	compared	_	_	VBN	_	_	_	_	_
33	to	_	_	TO	_	_	_	_	_
34	the	_	_	DT	_	_	_	_	_
35	NK/NKT	_	_	NNP	_	_	_	_	_
36	cell	_	_	NN	_	_	_	_	_
37	response	_	_	NN	_	_	_	_	_
38	in	_	_	IN	_	_	_	_	_
39	specific-pathogen-free	_	_	JJ	_	_	_	_	_
40	(	_	_	-LRB-	_	_	_	_	_
41	SPF	_	_	NN	_	_	_	_	_
42	)	_	_	-RRB-	_	_	_	_	_
43	control	_	_	NN	_	_	_	_	_
44	cats	_	_	NNS	_	_	_	_	_
45	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	early	_	_	JJ	_	_	_	_	_
3	control	_	_	NN	_	_	_	_	_
4	mechanism	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	Lm	_	_	NNP	_	_	_	_	_
7	does	_	_	VBZ	_	_	_	_	_
8	not	_	_	RB	_	_	_	_	_
9	rely	_	_	VB	_	_	_	_	_
10	on	_	_	IN	_	_	_	_	_
11	T	_	_	NN	_	_	_	_	_
12	cells	_	_	NNS	_	_	_	_	_
13	;	_	_	:	_	_	_	_	_
14	however	_	_	RB	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	a	_	_	DT	_	_	_	_	_
17	T	_	_	NN	_	_	_	_	_
18	cell	_	_	NN	_	_	_	_	_
19	response	_	_	NN	_	_	_	_	_
20	is	_	_	VBZ	_	_	_	_	_
21	required	_	_	VBN	_	_	_	_	_
22	for	_	_	IN	_	_	_	_	_
23	bacterial	_	_	JJ	_	_	_	_	_
24	clearance	_	_	NN	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	as	_	_	IN	_	_	_	_	_
27	demonstrated	_	_	VBN	_	_	_	_	_
28	by	_	_	IN	_	_	_	_	_
29	T	_	_	NN	_	_	_	_	_
30	cell-deficient	_	_	JJ	_	_	_	_	_
31	mice	_	_	NNS	_	_	_	_	_
32	that	_	_	WDT	_	_	_	_	_
33	are	_	_	VBP	_	_	_	_	_
34	able	_	_	JJ	_	_	_	_	_
35	to	_	_	TO	_	_	_	_	_
36	control	_	_	VB	_	_	_	_	_
37	but	_	_	CC	_	_	_	_	_
38	not	_	_	RB	_	_	_	_	_
39	clear	_	_	JJ	_	_	_	_	_
40	Lm	_	_	NN	_	_	_	_	_
41	infection	_	_	NN	_	_	_	_	_
42	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	seems	_	_	VBZ	_	_	_	_	_
3	that	_	_	IN	_	_	_	_	_
4	NK	_	_	NNP	_	_	_	_	_
5	cell	_	_	NN	_	_	_	_	_
6	production	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	interferon	_	_	NN	_	_	_	_	_
9	gamma	_	_	NN	_	_	_	_	_
10	after	_	_	IN	_	_	_	_	_
11	stimulation	_	_	NN	_	_	_	_	_
12	with	_	_	IN	_	_	_	_	_
13	IL-12	_	_	NNP	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	IL-18	_	_	NNP	_	_	_	_	_
16	plays	_	_	VBZ	_	_	_	_	_
17	an	_	_	DT	_	_	_	_	_
18	important	_	_	JJ	_	_	_	_	_
19	role	_	_	NN	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	Lm	_	_	NNP	_	_	_	_	_
22	control	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Several	_	_	JJ	_	_	_	_	_
2	studies	_	_	NNS	_	_	_	_	_
3	have	_	_	VBP	_	_	_	_	_
4	shown	_	_	VBN	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	NK	_	_	NNP	_	_	_	_	_
7	cell-depleted	_	_	JJ	_	_	_	_	_
8	mice	_	_	NNS	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	rats	_	_	NNS	_	_	_	_	_
11	fail	_	_	VBP	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	control	_	_	VB	_	_	_	_	_
14	initial	_	_	JJ	_	_	_	_	_
15	Lm	_	_	NN	_	_	_	_	_
16	infection	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	resulting	_	_	VBG	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	a	_	_	DT	_	_	_	_	_
21	higher	_	_	JJR	_	_	_	_	_
22	bacterial	_	_	JJ	_	_	_	_	_
23	burden	_	_	NN	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	whereas	_	_	IN	_	_	_	_	_
26	in	_	_	IN	_	_	_	_	_
27	normal	_	_	JJ	_	_	_	_	_
28	animals	_	_	NNS	_	_	_	_	_
29	infected	_	_	VBN	_	_	_	_	_
30	with	_	_	IN	_	_	_	_	_
31	Lm	_	_	NNP	_	_	_	_	_
32	,	_	_	,	_	_	_	_	_
33	NK	_	_	NNP	_	_	_	_	_
34	cells	_	_	NNS	_	_	_	_	_
35	are	_	_	VBP	_	_	_	_	_
36	recruited	_	_	VBN	_	_	_	_	_
37	from	_	_	IN	_	_	_	_	_
38	the	_	_	DT	_	_	_	_	_
39	blood	_	_	NN	_	_	_	_	_
40	to	_	_	TO	_	_	_	_	_
41	the	_	_	DT	_	_	_	_	_
42	spleen	_	_	NN	_	_	_	_	_
43	,	_	_	,	_	_	_	_	_
44	liver	_	_	NN	_	_	_	_	_
45	,	_	_	,	_	_	_	_	_
46	and/or	_	_	JJ	_	_	_	_	_
47	lymph	_	_	NN	_	_	_	_	_
48	nodes	_	_	NNS	_	_	_	_	_
49	,	_	_	,	_	_	_	_	_
50	and	_	_	CC	_	_	_	_	_
51	increased	_	_	VBN	_	_	_	_	_
52	NK	_	_	NN	_	_	_	_	_
53	cell	_	_	NN	_	_	_	_	_
54	activity	_	_	NN	_	_	_	_	_
55	is	_	_	VBZ	_	_	_	_	_
56	observed	_	_	VBN	_	_	_	_	_
57	during	_	_	IN	_	_	_	_	_
58	the	_	_	DT	_	_	_	_	_
59	first	_	_	JJ	_	_	_	_	_
60	days	_	_	NNS	_	_	_	_	_
61	of	_	_	IN	_	_	_	_	_
62	Lm	_	_	NN	_	_	_	_	_
63	infection	_	_	NN	_	_	_	_	_
64	.	_	_	.	_	_	_	_	_


1	Our	_	_	PRP$	_	_	_	_	_
2	objective	_	_	NN	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	present	_	_	JJ	_	_	_	_	_
6	study	_	_	NN	_	_	_	_	_
7	was	_	_	VBD	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	determine	_	_	VB	_	_	_	_	_
10	whether	_	_	IN	_	_	_	_	_
11	Treg	_	_	NNP	_	_	_	_	_
12	contribute	_	_	VBP	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	impaired	_	_	VBN	_	_	_	_	_
16	NK	_	_	NN	_	_	_	_	_
17	cell	_	_	NN	_	_	_	_	_
18	function	_	_	NN	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	FIV-infected	_	_	JJ	_	_	_	_	_
21	cats	_	_	NNS	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	reduced	_	_	VBN	_	_	_	_	_
25	capacity	_	_	NN	_	_	_	_	_
26	to	_	_	TO	_	_	_	_	_
27	clear	_	_	VB	_	_	_	_	_
28	Lm	_	_	NNP	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	hypothesized	_	_	VBD	_	_	_	_	_
3	that	_	_	IN	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	vivo	_	_	NN	_	_	_	_	_
6	Treg	_	_	NNP	_	_	_	_	_
7	cell	_	_	NN	_	_	_	_	_
8	depletion	_	_	NN	_	_	_	_	_
9	using	_	_	VBG	_	_	_	_	_
10	anti-feline	_	_	JJ	_	_	_	_	_
11	CD25	_	_	NN	_	_	_	_	_
12	monoclonal	_	_	JJ	_	_	_	_	_
13	antibody	_	_	NN	_	_	_	_	_
14	prior	_	_	JJ	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	innate	_	_	JJ	_	_	_	_	_
17	immune	_	_	JJ	_	_	_	_	_
18	challenge	_	_	NN	_	_	_	_	_
19	with	_	_	IN	_	_	_	_	_
20	Lm	_	_	NNP	_	_	_	_	_
21	would	_	_	MD	_	_	_	_	_
22	improve	_	_	VB	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	innate	_	_	JJ	_	_	_	_	_
25	immune	_	_	JJ	_	_	_	_	_
26	response	_	_	NN	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	clearance	_	_	NN	_	_	_	_	_
30	of	_	_	IN	_	_	_	_	_
31	bacteria	_	_	NN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_

